The endogenous small GTPase, Rac1, plays a critical role during normal skin wound healing. It remains to be determined whether endogenous Rac1 can be appropriately activated in chronic wounds; if not, whether exogenous Rac1 has therapeutic effects on wound healing. Here we show that Rac1 protein levels were lower in wounds of db/db diabetic mice than wounds in wild type mice during the healing process. To assess the therapeutic potential of exogenous Rac1 in wound healing, we produced a Tat-Rac1 fusion protein that enters into cells through protein transduction. Tat-Rac1 increased proliferation and migration of keratinocytes and dermal fibroblasts in vitro. Topical application of Tat-Rac1 accelerated cutaneous wound closure in vivo in db/db mice as well as wild type mice. Further analyses revealed that Tat-Rac1 had faster re-epithelialization, higher keratinocyte proliferation and migration without an earlier onset of myofibroblast activation than vehicle treated wounds. Tat-Rac1 also reduced inflammation in wounds. Our findings revealed the failure of diabetic wounds to elevate Rac1 expression and suggested a therapeutic strategy utilizing a Rac1-based biologic to compensate for this defect thereby promoting wound healing.
Introduction
Chronic skin wounds including pressure ulcers, diabetic foot ulcers and venous ulcers are serious medical problems worldwide. It has been reported those diseases affect 6.5 million patients in the United States alone. Together with aberrant healing in acute skin wounds (e.g., infection and scarring), the burden to treat these conditions exceeds $25 billion annually [1] . Strategies developing innovative targets to accelerate wound healing are based on the current mechanistic understanding of cutaneous wound healing. Cutaneous wound healing progresses through three distinct, yet overlapping phases: inflammation, tissue formation, and tissue remodeling [2] . Each phase is complex and involves coordinated interactions among tissue repair cells, growth factors and extracellular matrix [3] . Numerous Ivyspring International Publisher growth factors and cytokines have been shown to contribute to wound healing [3] . However, among them, only REGRANEX ® , a human PDGF-based therapeutic gel, is approved by the Food and Drug Administration (FDA) to treat diabetic wounds. These facts highlight a sense of urgency for scientific discovery-based therapeutic interventions. Various studies have identified Rac1, a small GTPase, as playing an important role in wound healing. Deletion or inhibition of Rac1 in either skin epidermis or oral epithelia resulted in delayed wound healing in the skin or the oral mucosa [4, 5] . Similarly, inducible deletion of the Rac1 gene in fibroblasts resulted in delayed wound closure with reduced collagen production and myofibroblast formation [6] . Conversely, transgenic mice expressing a constitutively active Rac1 in smooth muscle cells accelerate cutaneous wound repair through promoting angiogenesis [7] . In addition to its role in normal wound healing, a study reported that ganglioside GM3 depletion in diabetic mouse wounds improved healing by requiring IGF-1 receptor-mediated Rac1 activation to restore keratinocyte motility [8, 9] . Additionally, ultrasonic treatment-mediated promotion of wound healing in mouse models of diabetic and aging skin wounds involves activation of the calcium/CamKinaseII/Tiam1/Rac1 pathway that promotes fibroblast migration [10] . These data suggest that impaired wound healing lacks sufficient Rac1 activity and that activation of endogenous Rac1 should be explored as a therapeutic strategy to improve wound healing. In the present study, we sought to determine if Rac1 protein can be utilized pharmacologically to promote wound healing. Because Rac1 is an intracellular protein, it has to be delivered to the inside of cells to exert its functions. To this end, we employed a protein transduction strategy to deliver Rac1 into wounded cells. We chose a protein transduction peptide derived from the Tat protein of the HIV virus, and fused it to human Rac1 to create a Tat-Rac1 protein. Our study provides proof of principle for using Tat-Rac1 as a pharmacological biologic to promote cutaneous wound healing.
Materials and methods

Reagents and antibodies
Antibodies used in the present study were: guinea pig anti-K14 (RDI-Fitzgerald, Acton, MA), mouse anti-Rac1, rat anti-CD45, anti-BrdU FITC (BD Bioscience, San Jose, CA), mouse anti-V5 (Invitrogen, Grand Island, NY), mouse anti-GAPDH (Cell Signaling Technology, Danvers, MA), rabbit anti-α-smooth muscle actin (αSMA) (ABcam, Cambridge, UK), and rabbit anti-actin (Santa Cruz Biotechnology). For immunofluorescence (IF), Alexa Fluor 594 (red) or 488 (green) conjugated secondary antibodies (Invitrogen, Carlsbad, CA) were used. For αSMA immunohistochemistry (IHC), anti-rabbit secondary antibody (Vector Labs, Burlingame, CA) was used. All slides were mounted in Fluoromount G (Southernbio-tech, Birmingham, AL) with coverslips before microscopic examination.
Generation of Tat-Rac1 protein
Human Rac1 cDNA with 5' nucleotides encoding the Tat-tag (RKKRRQRRR) and 3' nucleotides encoding the V5 epitope (GLPIPNPLLGLDS) was cloned into the pET101TOPO protein expression vector (Invitrogen) upstream of the 6XHis-tag. The protein was produced in BL21 Star™ (DE3) E. coli and purified with a Ni-Sepharose column. Protein eluted from Ni-column was loaded onto a Sephacryl S200 size exclusion column (SEC) to separate Tat-Rac1 as a monomer. All reagents and buffers used in protein purification are endotoxin-free grade.
In vitro characterization of transduction and biological activity of Tat-Rac1 protein
WT primary mouse keratinocytes were isolated from neonatal mouse skin as previously described [11] . To test the biologic activity and ability of Tat-Rac1 to enter into cells, mouse keratinocytes, human HaCaT keratinocytes (from Thermo Fisher Scientific), or human dermal fibroblasts (ATCC, Manassas, VA) were cultured on the 8-well chamber slides for 12h, then Tat-Rac1 protein (1μg/ml) or BrdU (10μM) was added to the culture medium and incubated for 3h; slides were fixed in cold methanol for 5min and washed in PBS. V5 or BrdU were stained using anti-V5 or anti-BrdU antibodies. Cell proliferation response to Tat-Rac1 protein was evaluated by the percent of BrdU labelled cells in total counted cells. Each experiment was averaged from 8-well chambers; data from 3 separate experiments as mean ± SD.
In vitro keratinocyte migration assays
In vitro keratinocyte migration assays were performed as previously reported [12] . Briefly, WT cultured mouse keratinocytes or human HaCaT cells at 100% confluency in 6-well culture dishes were incubated with mitomycin C, 10µg/ml, (Sigma, St. Louis, MO) for 2 h to inhibit cell proliferation. A 1.2 mm diameter pipette tip was used to make the wound scratch. Tat-Rac1 (1.25µg/ml in mouse keratinocytes, 1.25µg/ml or 2.5µg/ml in HaCaT and human dermal fibroblasts), or equal volume vehicle PBS was added to media. Media in mouse keratinocyte culture was changed after 24h with the same concentration of Tat-Rac1. Cell migration was quantified using ImageJ for the scratched area occupied by migrating cells at different time points specified in Results. Each experiment was averaged from 6-well 3-mm dishes; data from 3 separate experiments as mean ± SD.
Animals and wound healing experiments
Experiments were performed in accordance with the National Institutes of Health Guidelines for the Care and Use of Laboratory Animals. The wound healing protocol was approved by the Institutional Animal Care and Use Committee at the University of Colorado Denver Anschutz Medical Campus. Hemizygous db/wt mice were purchased from the Jackson Laboratory (www.jax.org) with C57BL/6J background. We cross-bred db/wt and db/wt mice to generate db/db mice, and db/wt and wt/wt littermates were used as wildtype (WT) controls for wound healing experiments. Animals were housed under a 12 hours light/dark cycle in a SPF room with water and food provided ad libitum. For wounding experiments, of 8-10 week old mice were used for generation of skin wounds as previously reported [11] . Briefly, four full-thickness excisional wounds were made on the dorsal skin of anesthetized mice using a sterile 6-mm-diameter dermal punch. Tat-Rac1 [10ul phosphate buffered saline (PBS), doses specified in Results] was applied to each wound daily until day 8 when they are completely covered by scabs; treatment solution was allowed to dry before mice were returned to their cages. After day 10, Tat-Rac1 was topically applied to the gap between the scab and wound periphery to avoid the hard scab barrier. PBS (10µl/wound) was used as a vehicle control. Wound healing was evaluated by calculating both the wound area and the histological wound width from wound midline under microscopy.
Histology and Immunostaining analysis
An 8-mm diameter dermal punch symmetrically covering the entire wound was used to collect each wound sample. The whole wound was subjected to formalin fixation and paraffin embedding. Serial sections were cut from wound midline and H&E stained. The largest cross section of each wound was used for width measurement under microscopy. IF or IHC staining in tissue and cells were performed as previously described [12] . BrdU was quantified as the number of positive cells per mm migrating epidermis. CD45+ cells were quantified as positive cells per mm 2 stromal area directly under migrating epithelium. For quantification of IF images, we counted positive staining cells in four to five images from each wound and averaged them as one sample; 3 samples/group/time point were used for analyses.
Western blot analysis
Western blots were performed per our previous publication [12] 
Statistical Analysis
The Student's-test was used to compare two groups. The data are presented by mean±SD.
Results
Endogenous Rac1 expression in db/db and WT mice during wound healing
To examine endogenous Rac1 expression levels during wound healing, we performed excisional wound experiments with a 6-mm biopsy punch in WT and db/db mouse skin (db/db mice have delayed wound healing), and collected wounds with an 8-mm biopsy punch at different time points to examine Rac1 protein levels by western blot analysis (Fig 1A) . Rac1 protein was barely detectable in non-wounded skin in both WT and db/db mice. During wound healing, Rac1 protein levels gradually increased in WT wounds ( Figure 1A) ; in contrast, db/db mouse wounds had lower Rac1 protein levels compared to WT wounds for all time points examined. These results suggest that lower levels of Rac1 in db/db mice skin wounds might contribute to delayed wound closure when compared to WT mice wounds.
Tat-Rac1 protein promotes keratinocyte proliferation and migration
To test if exogenous Rac1 protein can overcome wound healing defects seen in db/db mice, we generated a Tat-Rac1 fusion protein, in which a protein transduction peptide (Tat) from the Tat protein of the HIV virus was fused with human Rac1 protein, and with a V5 peptide at the C-terminal of the protein to simplify detection of the recombinant protein ( Figure 1B ). Tat-Rac1 protein was purified using a size exclusion column (SEC) ( Figure 1C ). To verify its ability to enter keratinocytes, we added Tat-Rac1 protein to cultured mouse keratinocytes; immunofluorescence staining using a V5 antibody shows Tat-Rac1 protein entered into cells ( Figure 1D ). We then performed in vitro cell proliferation and migration assays with mouse keratinocytes, HaCaT human keratinocytes and human dermal fibroblasts to determine Tat-Rac1 bioactivities. For proliferation assays, we examined the number of BrdU labeled cells 12h after Tat-Rac1 treatment. In mouse keratinocytes, Tat-Rac1 treatment significantly increased the number of BrdU positive staining cells compared to control cells treated with PBS vehicle (Figure 2A, B) . Similarly, Tat-Rac1 also increased proliferation in HaCaT keratinocytes and dermal fibroblasts ( Figure  2C, 2D) . In cell migration assays, we examined mouse keratinocyte migration in response to Tat-Rac1 treatment ( Figure 2E, 2F) . By 24 hours after scratch wounding, when control keratinocytes began to migrate into the wound area, more than 50% of the wound area was covered by migrating cells treated with Tat-Rac1 protein. By 48 hours, Tat-Rac1 treated keratinocytes almost completely covered the scratch wounded area, whereas control keratinocytes only covered ~40% of the wounded area. We also found that Tat-Rac1 protein had a similar effect on migration in HaCaT keratinocytes and human dermal fibroblasts at 12h (Figure 2G , 2H) and 24h (not shown). These data indicated that Tat-Rac1 was biologically active. 
Topical application of Tat-Rac1 protein accelerated cutaneous wound healing in wild type and db/db mice
Next, we examined if topical application of Tat-Rac1 protein can promote wound healing in vivo. Based on clinical practice, diabetic wounds represent a common type of unhealed wound in humans, therefore, we generated wounds in db/db mice. Excisional wounds were made with a 6-mm diameter biopsy punch on the dorsal skin of 8-10 wks old db/db mice (both males and females). Gendermatched mice were divided into two groups for Tat-Rac1 protein (in10µl PBS) or equal volume of PBS-vehicle treatment, topically applied onto the wound area, starting immediately after punch biopsy (day 1). Based on in vitro experiments (Figure 2) showing the effective dose is likely in the µg range, we tested three doses of Tat-Rac1 (0.5, 1 and 2µg/wound, daily). While 0.5µg/wound had modest effects, 2µg/wound had no effect on promoting healing (not shown). We therefore focused on a1µg/wound dose for the remaining studies. With Tat-Rac1 treatment, accelerated wound closure was observed beginning on day 4 after wounding compared with PBS treatment (Figure 3A, B) . Tat-Rac1-treated db/db mice wounds were completely closed by day 13, whereas PBS treated wounds show slower healing for all time points. Histologically, Tat-Rac1 treated wounds were smaller in width and had longer epithelial migrating tongues by day 6 and day 8 compared to PBS controls ( Figure 3C, D) . On day 13, Tat-Rac1-treated mice had smaller stromal areas in the wound than untreated control mice (Fig 3C) . By staining wounded tissue with V5 antibody, Tat-Rac1 protein was detected in epidermal keratinocytes and stromal cells in the wound area ( Figure 3E ). We also performed western blot analysis using a V5 antibody to confirm the presence of Tat-Rac1 protein on day 8 wounds ( Figure 3F ).
Next, we tested if Tat-Rac1 application could also provide benefits to normal wound healing. Gender-matched 8-10 week-old WT mice were used for Tat-Rac1 and PBS groups with 6-mm punch skin biopsies. Tat-Rac1 treated wounds exhibited accelerated healing compared to PBS treated wounds starting from day 2 to day 9 ( Figure 4A, B) . Histological analysis showed that Tat-Rac1 treated wounds had longer epidermal migrating tongues than control wounds on day 5 and day 8 ( Figure 4C,  D) . By day 9, when wound closure was complete in both groups, Tat-Rac1 treated wounds had smaller wound remodeling areas than control group.
Increased keratinocyte proliferation contributed to Tat-Rac1-mediated wound healing acceleration
Due to Tat-Rac1's ability to promote keratinocyte proliferation in vitro (Figure 2) , we examined whether topical application of Tat-Rac1 on wounds increased keratinocyte proliferation during wound healing in vivo. Mice were injected with BrdU 2h before harvesting wound tissue samples; sections were subsequently stained for BrdU using immunofluorescence. In both db/db and WT mice, all Tat-Rac1 treated wounds had higher numbers of BrdU positive cells compared to PBS treated control wounds ( Figure  5A-D) .
Reduced inflammation but not myofibroblast numbers in Tat-Rac1 treated wound stroma
Inflammation plays a critical role in the process of wound healing and excessive inflammation is one of the characteristics of chronic wounds. To determine how Tat-Rac1 treatment affects this process, we compared the number of CD45+ leukocytes in db/db and WT control wounds with or without Tat-Rac1 treatment. Compared to PBS vehicle treatment, the number of CD45+ cells in wound stroma were decreased in both db/db and WT mice after Tat-Rac1 treatment during the early stage of wound healing ( Figure 6A-D) .
Fibroblast activation is the basis of wound contraction and stromal regeneration, but excessive fibroblast activation can also cause fibrotic scarring. We performed IHC for αSMA, a marker for fibroblast activation and myofibroblast formation. Tat-Rac1 treatment did not induce earlier onset αSMA positive cells or increase αSMA positive cells before day 8 in db/db wounds or day 5 in WT wounds (not shown). Cells positive for αSMA began to appear in granulation tissue (wound stroma) after these time points (Figure 6E, 6F) . On day 8 db/db wounds or day 5 WT wounds, αSMA staining was moderately broader or intense in some areas ( Figure 6E, 6F) . In db/db day 13 wounds, even though re-epithelialization was completed in both groups ( Figure 6E ), αSMA positive cells were retained in granulation tissue, suggesting that wound remodeling was not complete. However, in WT day 9 wounds, where the area of granulation tissue was smaller in Tat-Rac1 treated wound than PBS treated wound, αSMA positive cells had largely disappeared in Tat-Rac1 treated granulation tissue ( Figure 6F ), suggesting that topically applied Tat-Rac1 does not have a sustained effect on fibroblast activation once the treatment is stopped. 
Discussion
In the current study, we found that wounds in db/db mice had a delayed increase in Rac1 protein and lower levels compared to wounds in WT mice. This defect was partially overcome by delivery of exogenous Tat-Rac1 protein to wounds in db/db mice. This result is consistent with our previous study indicating that increased total Rac1 protein results in Rac1 activation that promotes healing of oral mucositis lesions [12] .
Similar to our findings, a previous study reported that intravitreal injection of a constitutively active Tat-Rac1 protein for two weeks improved retina ganglion cell survival and regeneration [13] . Because constitutively active Rac1 is commonly expressed in human cancer [14] and treating diabetic wounds in patients could require extended treatment regimens, it is critical to avoid potential oncogenic effects from Rac1, as Rac1 activation is an important mechanism for cancer cell migration and metastasis [15] . Another consideration is the amount of Tat-Rac1 to use in wound healing, as cancer cells express much higher levels of Rac1 than normal cells [16, 17] . For these reasons, we did not use constitutively active Rac1, and also used a relatively low amount of Tat-Rac1 to treat wounds in vivo. The combination of using normal (not constitutively active) Rac1 with a low dose could attribute to a relatively modest effect of Rac1 on db/db wounds. However, the same dose of Tat-Rac1 had more profound effects promoting healing in WT wounds than in db/db wounds ( Figure  3 vs. Figure 4) . It is possible that although the Tat-Rac1-mediated epidermal proliferation, migration and reduced inflammation found in our study contributes to healing in both db/db and WT wounds, the profound defects in these processes in db/db wounds compared to WT wounds require a higher therapeutic dose or a more active form of Tat-Rac1. It is also probable that some of the defects in db/db wound healing are not Rac1 targets thus cannot be corrected by Rac1 activation alone. These possibilities require future studies to identify the underlying mechanisms. The effect of Tat-Rac1 on accelerating wound healing in normal mice is a bit surprising to us, as endogenous Rac1 is already elevated in response to wounding (Figure 1 ). Rac1 has been reported to promote proliferation in both keratinocytes and fibroblasts [4] [5] [6] 10] and our in vitro studies also show that Tat-Rac1 promoted proliferation and migration in both cell types (Figure 2 ). Because wound contraction contributes to wound closure in our wound healing model [18] , it is important to determine if Tat-Rac1 promotes wound closure through keratinocytemediated re-epithelialization or/and fibroblast activation-induced wound contraction. We found that the in vivo effect of Tat-Rac1 was primarily in the wounded epidermis without early onset myofibroblast activation in granulation tissue of wounded skin ( Figure 6F ). Since Tat-Rac1 transduced both epidermal and dermal cells in vivo (Figure 3) , these results suggest that the role of Rac1 in fibroblast activation is largely dispensable by other stimuli in the wound milieu. For example, transforming growth factor-β (TGFβ), a potent fibroblast activator, is elevated in wounds [19] . Further, αSMA + fibroblasts did not linger after wound remodeling in Tat-Rac1 treated WT wounds ( Figure 6F ), suggesting that once Tat-Rac1 topical application is stopped, there is no sustained effect on fibroblast activation. Our data prompt future studies using models systems that more closely mimic acute surgical wounds and diabetic wounds in humans [18, 20] to further determine the effects of Tat-Rac1topical application on acute and chronic wounds.
Prolonged inflammation is one of the hallmark characteristics of chronic wounds [21] . We found that Tat-Rac1 treated wounds had reduced leukocyte infiltration prior to complete wound closure, suggesting that reduced inflammation by Tat-Rac1 could contribute to accelerated wound closure. Previous studies regarding the role of Rac1 in skin inflammation are controversial. Pedersen et al. have found that keratinocyte-restricted deletion of Rac1 promoted skin inflammation in an contact dermatitis model [22] . In contrast, Winge et al. showed that constitutive Rac1 is consistently elevated in psoriatic epidermis and that transgenic mice expressing a constitutively active form of Rac1 in the epidermis developed lesions similar to those in human psoriasis with aberrant activation of immune cells [23] . These paradoxical results from different model systems indicate that the effect of Rac1 on inflammation could depend on the amount of Rac1 protein as well as the disease context. In combination, these factors differentially affect Rac1 in regulating interactions between keratinocyte and immune cell.
In summary, our study revealed delayed and low levels of Rac1 expression in response to wounding in db/db mice. Our study demonstrates the feasibility of topical, short-term application of a Rac1-based biologic to promote wound healing in both normal and diabetic wounds. Future studies will assess dose-dependent efficacy of Tat-Rac1 as a therapeutic agent and potential side effects, particularly oncogenic effects as a consequence of treatment.
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